Cipla Ltd.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that following the inspection by the United States Food and Drug Administration (USFDA) at the Invagen (US) manufacturing facility from December 2, 2019 to December 6, 2019, the Company has received the Establishment Inspection Report (EIR), indicating closure of the inspection. 

The above information is a part of company’s filings submitted to BSE.